The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each vaccination
Timeframe: Within 30 minutes after each vaccination
Presence of solicited administration site reactions within 7 days after vaccination
Timeframe: Within 7 days after vaccination
Presence of solicited systemic reactions within 7 days after vaccination
Timeframe: Within 7 days after vaccination
Presence of unsolicited AEs within 28 days after vaccination
Timeframe: Within 28 days after vaccination
Presence of serious adverse events (SAEs)
Timeframe: Within 6 months after vaccination
Presence of adverse events of special interest (AESIs)
Timeframe: Within 6 months after vaccination
Presence of related SAEs throughout the study
Timeframe: Throughout the study, approximately 12 months
Presence of related AESIs throughout the study
Timeframe: Throughout the study, approximately 12 months
Presence of related fatal SAEs throughout the study
Timeframe: Throughout the study, approximately 12 months
Presence of out-of-range biological test results (including shift from baseline values)
Timeframe: Within 7 days after vaccination